• OPEN AN ACCOUNT
Indian Indices
Sensex
85,408.70 -116.14
( -0.14%)
Global Indices
Nasdaq
48,752.17 288.75
(0.60%)
Dow Jones
6,952.35 21.56
(0.31%)
Hang Seng
50,381.79 37.69
(0.07%)
Nikkei 225
9,870.68 -18.54
(-0.19%)
Forex
USD-INR
89.57 -0.04
(-0.05%)
EUR-INR
105.52 0.34
(0.32%)
GBP-INR
120.86 0.52
(0.43%)
JPY-INR
0.57 0.00
(0.60%)

EQUITY - MARKET SCREENER

Sahasra Electronic Solutions Ltd
Industry :  Electronics - Components
BSE Code
ISIN Demat
Book Value()
93258
INE0RBQ01018
90.7562973
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SAHASRA
84.98
705.17
EPS(TTM)
Face Value()
Div & Yield %
3.32
10
0
 

Alembic Pharma receives USFDA approval for Travoprost ophthalmic solution
Dec 18,2025
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Travatan Z Ophthalmic Solution, 0.004%, marketed by Sandoz Inc. Travoprost ophthalmic solution is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

According to IQVIA, Dasatinib tablets have an estimated market size of US$ 61 million for the 12 months ending September 2025.

With this approval, Alembic has a cumulative total of 232 ANDA approvals from the USFDA, including 212 final approvals and 20 tentative approvals.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.

The company’s consolidated net profit jumped 20.40% to Rs 184.71 crore in Q2 FY26, compared to Rs 153.41 crore posted in Q2 FY25. Revenue from operations grew 15.90% year on year (YoY) to Rs 1,910.15 crore in Q2 September 2025.

Shares of Alembic Pharmaceuticals shed 0.34% to Rs 844 on the BSE.